daewoong jeuveau botulinum toxin

South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin...

Medytox Inc. said in a regulatory filing on Wednesday that it is selling off approximately 2.19 million shares of Evolus, Daewoong Pharmaceutical's ...

Daewoong Pharmaceutical said Friday that it has obtained marketing authorization from Ecuador's National Agency for Health Regulation, Control and S...

Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wri...

South Korea's Daewoong Pharmaceutical has licensed a new drug candidate for idiopathic pulmonary fibrosis (IPF) to CS Pharmaceuticals (CSP) of the U...

South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical pr...

Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Ja...

Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...

South Korea's biopharmaceutical company Medytox Inc. will build a plant for finished products containing botulinum toxin in the United Arab Emirates...

Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...

South Korea's drug company Daewoong Pharmaceutical said on Wednesday that it has signed an agreement with biopharmaceutical venture Neurorive to joi...

South Korea's leading drug company Daewoong Pharmaceutical is accelerating its global expansion efforts for its 34th domestically developed drug Fex...

DAEWOONG PHARMACEUTICAL has received domestic approval for its diabetes drug Envlo with the active ingredient enavogliflozin, the second straight ye...

South Korea’s Daewoong Pharmaceutical Co. has obtained approval for the sale of its botulinum toxin product, Nabota, in Saudi Arabia and Ukrai...

South Korean pharmaceutical company Medytox Inc. has filed a complaint with the International Trade Commission (ITC) against Hugel Inc., alleging th...

South Korea-based Daewoong Pharmaceutical Co. is hoping to achieve 5 trillion won ($4.4 billion) in sales by 2027, meaning that the company aims to ...